a Clinical Medicine Division , Korea Institute of Oriental Medicine , Daejeon , Republic of Korea.
b Department of Oriental Medicine Biotechnology , Kyung Hee University , Yongin , Republic of Korea.
Pharm Biol. 2019 Dec;57(1):90-98. doi: 10.1080/13880209.2018.1564929.
Lespedeza cuneata G. Don (Fabaceae), has been used as a traditional treatment of various diseases. There is a report L. cuneata effects on hormone replacement therapy for endocrine-related disease. However, studies related to benign prostatic hyperplasia (BPH) have not been investigated.
The effects of L. cuneata aqueous extract (LCW) on testosterone-induced prostatic hyperplasia (TPH) were examined.
Male Wistar rats (10 weeks, 330-350 g) were randomly divided to 6 groups (n = 6): Control group; TPH group (3 mg/kg, s.c, daily); TPH + LCW (25, 50, 100 mg/kg); TPH + Finasteride 10 mg/kg for 6 weeks. At the end of treatment, histological change of prostate, serum dihydrotestosterone (DHT) level, mRNA expression of 5α-reductase, inflammatory factors, proliferating cell nuclear antigen (PCNA) and fibroblast growth factor-2 (FGF-2) in prostate were examined. Then, LCW was treated with BPH-1, a human BPH cell line, at 25, 50, 100 μg/mL for 24 h and examine mRNA level of androgen receptor (AR) and prostate-specific antigen (PSA). In addition, the content of vicenin-2 was analyzed.
LCW treatment of TPH inhibited serum DHT levels by 54.5, 51.2 and 54.1% and mRNA expression of 5α-reductase were inhibited 54.3, 61.3 and 73.6%, respectively. In addition, mRNA expression of inflammatory factors, PCNA and FGF-2 were decreased in the prostate of rats. Also, LCW attenuated mRNA level of AR and PSA in BPH-1 cell. The content of vicenin-2 in the LCW was analyzed to 0.89 mg/g.
Based on the results, LCW is a potential pharmacological candidate for the treatment of prostatic hyperplasia.
胡枝子（豆科）已被用作治疗各种疾病的传统药物。有报道称，胡枝子对激素替代疗法治疗与内分泌相关的疾病有效果。然而，关于良性前列腺增生（BPH）的研究尚未进行。
研究胡枝子水提物（LCW）对睾丸酮诱导的前列腺增生（TPH）的影响。
雄性 Wistar 大鼠（10 周龄，330-350g）随机分为 6 组（n=6）：对照组；TPH 组（3mg/kg，sc，每天）；LCW（25、50、100mg/kg）；TPH+LCW（25、50、100mg/kg）；阳性对照药非那雄胺 10mg/kg。治疗 6 周后，观察前列腺组织学变化，检测血清中二氢睾酮（DHT）水平、5α-还原酶 mRNA 表达、前列腺内炎性因子、增殖细胞核抗原（PCNA）和纤维母细胞生长因子-2（FGF-2）的表达。然后，将 LCW 以 25、50、100μg/ml 处理 BPH-1 人前列腺增生细胞 24h，检测雄激素受体（AR）和前列腺特异性抗原（PSA）的 mRNA 水平。此外，还分析了 vicenin-2 的含量。
LCW 可降低 TPH 大鼠血清 DHT 水平（降低 54.5%、51.2%和 54.1%）和 5α-还原酶 mRNA 表达（降低 54.3%、61.3%和 73.6%）。此外，LCW 还可降低前列腺内炎性因子、PCNA 和 FGF-2 的 mRNA 表达。LCW 还可降低 BPH-1 细胞中 AR 和 PSA 的 mRNA 水平。LCW 中 vicenin-2 的含量为 0.89mg/g。
基于这些结果，LCW 可能是治疗前列腺增生的潜在药物候选物。
